Skip to content
  • YouTube
  • Facebook
  • LinkedIn
Pharm'Up

Pharm'Up

An E-platform for Learners

https://www.youtube.com/watch?v=xuTKPPZrxy4
Primary Menu
  • Home
  • News
  • Industries
  • Disease
  • Drugs
  • Events
  • Jobs
  • Trainings
  • Conferences
  • Syllabus
  • Previous Papers
  • Notes
  • Colleges
Live
  • Home
  • 2026
  • November
  • 8
  • Centre Proposes Immediate Suspension of Drug Manufacturing Licences Over Critical Quality Failures
  • Pharma News

Centre Proposes Immediate Suspension of Drug Manufacturing Licences Over Critical Quality Failures

Pharm'Up 2 min read

The Union Ministry of Health and Family Welfare has introduced sweeping regulatory proposals to amend the Drugs Rules, 1945, aimed at radically overhauling India’s post-market drug surveillance and enforcement framework. The proposed framework targets immediate, unbuffered punitive action against manufacturing facilities whose products fail critical quality parameters, sealing historical loopholes that previously allowed substandard medications to remain commercially active during prolonged administrative proceedings.

Key Regulatory Highlights and Structural Changes

  • Immediate License Suspension for NSQ Findings: Under the newly drafted provisions, both the Central Licensing Approving Authority and respective State Licensing Authorities are empowered to enforce an immediate halt to manufacturing operations upon receiving an adverse Government Analyst report. This immediate intervention applies specifically when drugs are flagged as Not of Standard Quality (NSQ) due to core structural failures in:
    • Assay: Ensuring the active pharmaceutical ingredient (API) meets precise potency and quantitative therapeutic standards.
    • Dissolution: Guaranteeing proper release rates of the active drug within the body.
    • Related Substances & Impurities: Controlling toxic byproducts, degradation elements, and chemical contaminants.
    • Sterility: Preventing microbial contamination in injectable, ophthalmic, and other sterile dosage forms.
  • Elimination of the Regulatory Time-Gap: Historically, the suspension or cancellation of a manufacturing licence necessitated formal show-cause notices and procedural deliberations. This created a dangerous window where suspect drug batches remained in distribution pipelines. The amendments eliminate this administrative delay to minimize patient exposure risks.
  • Strict Revocation and Compliance Prerequisites (RCA & CAPA): Suspension is not merely a temporary penalty; its reversal is tied to verifiable scientific remediation. Manufacturers are legally obligated to execute an exhaustive Root Cause Analysis (RCA) and implement robust Corrective and Preventive Action (CAPA) protocols. Resumption of manufacturing is strictly conditioned upon on-site or documented verification by the Licensing Authority confirming that the underlying quality failures have been permanently addressed.
  • Streamlined Inter-Agency Reporting (Form 13 Revisions): To resolve historical silos between federal and state regulators, the amendments mandate enhanced endorsement protocols for Form 13 test reports. Official findings will be simultaneously transmitted to the Drugs Controller General of India (DCGI), jurisdictional State and Union Territory regulators, and the associated marketers and manufacturers, significantly enhancing cross-jurisdictional accountability.

Origin and Public Consultation Phase

The reform proposals originate from comprehensive multi-stakeholder deliberations, specifically tracing back to the 65th meeting of the Drugs Consultative Committee (DCC) on December 20, 2024, followed by critical scientific and regulatory backing during the 92nd meeting of the Drugs Technical Advisory Board (DTAB) on April 24, 2025.

The Ministry has formally notified the draft amendments in the Gazette of India, opening a 30-day window for industry stakeholders, clinical experts, consumer advocacy groups, and the public to submit objections, commentaries, and constructive suggestions.

About the Author

Pharm'Up

Author

An E-platform for Pharma Learners

View All Posts

Post navigation

Previous: Pharmacovigilance Assistant Recruitment: Indian Pharmacopoeia Commission (IPC) Hiring at SVIMS, Tirupati

Related Stories

Pharm up 385
2 min read
  • Pharma News

Targeting RNA Modification: FTO Enzyme Emerges as a Biomarker and Therapeutic Target in Gastrointestinal Cancers

Pharm'Up
Pharm up 384
2 min read
  • Pharma News

Advancing Oncology Care: Zydus and Formycon Secure USFDA BLA Acceptance for FYB206, the First Publicly Announced Keytruda Biosimilar

Pharm'Up
Pharm up 383
2 min read
  • Pharma News

Strengthening Regulatory Oversight: India Proposes Strict Advertising Bans on Prescription Drugs for Retailers and Wholesalers

Pharm'Up

Recent Posts

  • Centre Proposes Immediate Suspension of Drug Manufacturing Licences Over Critical Quality Failures
  • Pharmacovigilance Assistant Recruitment: Indian Pharmacopoeia Commission (IPC) Hiring at SVIMS, Tirupati
  • AIIMS Jodhpur Recruitment: Project Research Scientist-I Position in Neurosurgery
  • AYUSH-CCRUM Funded Senior Research Fellow (SRF) Position at INST Mohali
  • Research Fellowships at AIIMS Jodhpur: Openings for Research Associate-III

Recent Comments

No comments to show.

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025

Categories

  • Colleges
  • Conferences/ Workshops
  • Disease
  • Drugs
  • Events
  • Industries
  • Notes
  • Pharma Jobs
  • Pharma News
  • Previous Papers
  • Syllabus
  • Trainings/ Courses
  • Uncategorized

Read These Too

Pharm up 406
2 min read
  • Pharma News

Centre Proposes Immediate Suspension of Drug Manufacturing Licences Over Critical Quality Failures

Pharm'Up
Pharm up 405
2 min read
  • Pharma Jobs

Pharmacovigilance Assistant Recruitment: Indian Pharmacopoeia Commission (IPC) Hiring at SVIMS, Tirupati

Pharm'Up
Pharm up 403
2 min read
  • Pharma Jobs

AIIMS Jodhpur Recruitment: Project Research Scientist-I Position in Neurosurgery

Pharm'Up
Pharm up 402
1 min read
  • Pharma Jobs

AYUSH-CCRUM Funded Senior Research Fellow (SRF) Position at INST Mohali

Pharm'Up
  • YouTube
  • Facebook
  • LinkedIn
Copyright ©Pharm'UP All rights reserved by Eduversity India | MoreNews by AF themes.